1
|
Zhu L, Zhang Y, Yang J, Wang Y, Zhang J, Zhao Y, Dong W. Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model. Eur J Drug Metab Pharmacokinet 2015; 41:395-402. [PMID: 25753830 DOI: 10.1007/s13318-015-0271-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Accepted: 02/23/2015] [Indexed: 12/27/2022]
Abstract
This study developed a physiologically based pharmacokinetic (PBPK) model in intraabdominally infected rats and extrapolated it to humans to predict the levofloxacin pharmacokinetics and penetration into tissues. Twelve male rats with intraabdominal infections induced by Escherichia coli received a single dose of 50 mg/kg body weight of levofloxacin. Blood plasma was collected at 5, 10, 20, 30, 60, 120, 240, 480 and 1440 min after injection, respectively. A PBPK model was developed in rats and extrapolated to humans using GastroPlus software. The predictions were assessed by comparing predictions and observations. In the plasma concentration-versus-time profile of levofloxacin in rats, C max was 23.570 μg/ml at 5 min after intravenous injection, and t1/2 was 2.38 h. The plasma concentration and kinetics in humans were predicted and validated by the observed data. Levofloxacin penetrated and accumulated with high concentrations in the heart, liver, kidney, spleen, muscle and skin tissues in humans. The predicted tissue-to-plasma concentration ratios in abdominal viscera were between 1.9 and 2.3. When rat plasma concentrations were known, extrapolation of a PBPK model was a method to predict the drug pharmacokinetics and penetration in humans. Levofloxacin had good penetration into the liver, kidney and spleen as well as other tissues in humans. This pathological model extrapolation may provide a reference for the study of antiinfective PK/PD. In our study, levofloxacin penetrated well into abdominal organs. Also ADR monitoring should be implemented when using levofloxacin.
Collapse
Affiliation(s)
- Liqin Zhu
- Pharmacy Department, Tianjin First Center Hospital, No. 24 Fukang Road, Nankai District, Tianjin, 300192, China.
| | - Yuan Zhang
- Pharmacy Department, Tianjin First Center Hospital, No. 24 Fukang Road, Nankai District, Tianjin, 300192, China
| | - Jianwei Yang
- Tianjin Medical University, Tianjin, 300070, China
| | | | - Jianlei Zhang
- Pharmacy Department, Tianjin First Center Hospital, No. 24 Fukang Road, Nankai District, Tianjin, 300192, China
| | - Yuanyuan Zhao
- The 153 Central Hospital of the Chinese People's Liberation Army, Henan, 450000, China
| | - Weilin Dong
- Tianjin Medical University, Tianjin, 300070, China
| |
Collapse
|
2
|
Cao G, Zhang J, Wu X, Yu J, Chen Y, Ye X, Zhu D, Zhang Y, Guo B, Shi Y. Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. J Clin Pharm Ther 2013; 38:394-400. [PMID: 23701411 PMCID: PMC4285945 DOI: 10.1111/jcpt.12074] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Accepted: 04/29/2013] [Indexed: 11/29/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE The pharmacokinetics (PK) and pharmacodynamics (PD) of levofloxacin were investigated following administration of levofloxacin injection in healthy Chinese volunteers for optimizing dosing regimen. METHODS The PK study included single-dose (750 mg/150 mL) and multiple-dose (750 mg/150 mL once daily for 7 days) phases. The concentration of levofloxacin in blood and urine was determined using HPLC method. Both non-compartmental and compartmental analyses were performed to estimate PK parameters. Taking fC(max) /MIC ≥5 and fAUC(24 h) /MIC ≥30 as a target, the cumulative fraction of response (CFR) of levofloxacin 750 mg for treatment of community-acquired pneumonia (CAP) was calculated using Monte Carlo simulation. The probability of target attainment (PTA) of levofloxacin at various minimal inhibitory concentrations (MICs) was also evaluated. RESULTS AND DISCUSSION The results of PK study showed that the C(max) and AUC(0-∞) of levofloxacin were 14·94 μg/mL and 80·14 μg h/mL following single-dose infusion of levofloxacin. The half-life and average cumulative urine excretion ratio within 72 h post-dosing were 7·75 h and 86·95%, respectively. The mean C(ss,max), C(ss,min) and AUC(0-τ) of levofloxacin at steady state following multiple doses were 13·31 μg/mL, 0·031 μg/mL and 103·7 μg h/mL, respectively. The accumulation coefficient was 1·22. PK/PD analysis revealed that the CFR value of levofloxacin 750-mg regimen against Streptococcus pneumoniae was 96·2% and 95·4%, respectively, in terms of fC(max) /MIC and fAUC/MIC targets. WHAT IS NEW AND CONCLUSION The regimen of 750-mg levofloxacin once daily provides a satisfactory PK/PD profile against the main pathogenic bacteria of CAP, which implies promising clinical and bacteriological efficacy for patients with CAP. A large-scale clinical study is warranted to confirm these results.
Collapse
Affiliation(s)
- G Cao
- Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Bosca F. Seeking to Shed Some Light on the Binding of Fluoroquinolones to Albumins. J Phys Chem B 2012; 116:3504-11. [DOI: 10.1021/jp208930q] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Francisco Bosca
- Instituto
de Tecnología Química
UPV - CSIC, Universidad Politécnica de Valencia, Avda de los Naranjos s/n, 46022 Valencia,
Spain
| |
Collapse
|
4
|
Pelly L. IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: focus on gatifloxacin. Adv Ther 2002; 19:229-42. [PMID: 12539883 DOI: 10.1007/bf02850363] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
The majority of the 1.1 million patients hospitalized for community-acquired pneumonia (CAP) in the United States begin therapy with an intravenous antibiotic. A switch to oral therapy as soon as patients are clinically stable reduces the length of hospitalization and associated costs. Fluoroquinolones are appropriate candidates for switch therapy. Gatifloxacin is an excellent choice when a fluoroquinolone is being considered for sequential switch therapy in the treatment of CAP requiring hospitalization.
Collapse
|
5
|
Sahloff EG, Smith BP, Martin SJ. Fluoroquinolone E-Testing against Pseudomonas Aeruginosa and Streptococcus Pneumoniae. J Pharm Technol 2002. [DOI: 10.1177/875512250201800503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Objectives and Design: The use of fluoroquinolones has increased against antibiotic-resistant pathogens such as Streptococcus pneumoniae and Pseudomonas aeruginosa. The E-test (AB Biodisk, Solna, Sweden) is now commonly used for susceptibility testing of fluoroquinolones against these organisms. The purpose of the present study was to evaluate the accuracy and correlation of minimum inhibitory concentrations (MICs) determined by E-testing with a National Committee for Clinical Laboratory Standards reference standard, agar-dilution MIC testing. E-test and agar dilution MICs were compared for ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin against clinical isolates of S. pneumoniae (n = 53) and P. aeruginosa (n = 62). Main Outcome Measures: MICs were determined by use of agar dilution and E-test methods. Essential agreement was defined as MICs from both methods within ± 1 log2 dilution. Categorical agreement compared MIC interpretations: susceptible, intermediate, or resistant. Categorical disagreement between methods was reported as very major, major, or minor errors. Results: E-tests produced lower MICs than the reference method for ciprofloxacin, gatifloxacin, and moxifloxacin versus P. aeruginosa. For S. pneumoniae, E-test MICs tended to be higher for all fluoroquinolones. The best correlation between testing methods was seen with levofloxacin. Essential agreement occurred more frequently with P. aeruginosa in the lower range of MICs and with S. pneumoniae in the higher range of MICs. Categorical agreement was greater than 90% for the 460 comparisons. Two very major errors (false-susceptible) occurred for gatifloxacin versus P. aeruginosa. Conclusions: For the determination of fluoroquinolone susceptibility against S. pneumoniae and P. aeruginosa, E-testing is a simple tool for clinical use, and few very major or major errors in susceptibility interpretation occur for either organism. For determining fluoroquinolone MICs, E-testing may overestimate drug activity against P. aeruginosa and underestimate drug activity versus S. pneumoniae compared with the agar dilution method. These differences could affect appropriate antimicrobial selection, leading to suboptimal outcomes.
Collapse
Affiliation(s)
- Eric G Sahloff
- ERIC G SAHLOFF PharmD, Infectious Disease/Critical Care Pharmacotherapy Fellow, College of Pharmacy, University of Toledo, Toledo, OH
| | - Benjamin P Smith
- BENJAMIN P SMITH BS, PharmD Student, College of Pharmacy, University of Toledo
| | - Steven J Martin
- STEVEN J MARTIN PharmD BCPS FCCM, Director, The Infectious Disease Research Laboratory; Associate Professor, College of Pharmacy, University of Toledo
| |
Collapse
|
6
|
Kays MB, Graff MA. Broth microdilution and E-test for determining fluoroquinolone activity against Streptococcus pneumoniae. Ann Pharmacother 2002; 36:416-22. [PMID: 11895052 DOI: 10.1345/aph.1a119] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVE To compare broth microdilution and E-test minimum inhibitory concentrations (MICs) of 4 fluoroquinolones against Streptococcus pneumoniae and to determine the effect of these in vitro MIC methods on the calculation of AUC00-24/MIC ratios. METHODS Levofloxacin, gatifloxacin, moxifloxacin, and gemifloxacin MICs were determined by broth microdilution (incubated in air) and E-test (incubated in CO2) for 100 clinical isolates of S. pneumoniae. MIC50, MIC90, and geometric mean MIC were calculated. Steady-state serum concentration-time profiles were simulated for once-daily, oral dosing of levofloxacin 500 mg, gatifloxacin 400 mg, moxifloxacin 400 mg, and gemifloxacin 320 mg. After correcting for protein binding, AUC0-24 of unbound drug was calculated for each regimen, and AUC0-24/MIC ratios were calculated using MIC data from both in vitro methods. Differences in MICs between methods were determined for each agent using the paired t-test (after logarithmic transformation of MICs) and the Wilcoxon signed-rank test. Differences in AUC0-24/MIC ratios were also determined using the paired t-test and the Wilcoxon signed-rank test. The level of significance for all analyses was p < 0.05. RESULTS Broth microdilution and E-test MICs were within +/- 1 log2 dilution for 94%, 93%, 61%, and 35% of the isolates for levofloxacin, gatifloxacin, moxifloxacin, and gemifloxacin, respectively. Broth microdilution MICs were significantly lower than E-test MICs for all 4 agents (p < 0.001). However, a categorical change in susceptibility was seen for only 1 isolate with gatifloxacin and moxifloxacin (intermediate by broth microdilution, resistant by E-test). AUC0-24/MIC ratios were significantly higher for each regimen when MICs were determined by broth microdilution compared with E-test (p < 0.001). CONCLUSIONS There is a significant difference in the activity of the newer fluoroquinolones against S. pneumoniae when MICs are determined by broth microdilution and E-test. When evaluating fluoroquinolone activity and pharmacodynamics against this organism, clinicians must be aware that MIC testing methodology may have a significant impact on the results.
Collapse
Affiliation(s)
- Michael B Kays
- School of Pharmacy and Pharmacal Sciences, Purdue University, Indianapolis, IN 46202-2879, USA.
| | | |
Collapse
|
7
|
Rodvold KA. Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside. Pharmacotherapy 2001; 21:319S-330S. [PMID: 11714223 DOI: 10.1592/phco.21.18.319s.33904] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Applied pharmacokinetics has long been a lifeline of clinical pharmacy services. National surveys during the past decade documented clinical pharmacy services and demonstrated that a substantial rate of growth occurred in clinical pharmacokinetic consultations and management of drug therapy protocols. Pharmacodynamic principles of antiinfective agents are rapidly becoming a new paradigm of clinical pharmacy services. beta-Lactams, aminoglycosides, and fluoroquinolones represent the three classes of antiinfective agents that have made the most progress toward the clinical applications of pharmacodynamics. Pharmacodynamic parameters are being used to select and compare agents within an antiinfective class (e.g., fluoroquinolones), make modifications in the dosage (e.g., extended-interval dosing of aminoglycosides) and/or mode of administration (e.g., continuous infusion of beta-lactams), develop in vivo breakpoint determinations, and assess the development of bacterial resistance. In addition, pharmacodynamic parameters have influenced the clinical drug development of new (e.g., linezolid) and older (amoxicillin-clavulanate, fluoroquinolones) antiinfective agents. Further investigations are needed to explore the clinician's use of validated prediction methods and patient-specific pharmacodynamic parameters at the bedside. By linking pharmacokinetic services with pharmacodynamic principles, the opportunity for continued progress toward our assessment and decisions for successful clinical outcomes is possible with old and new antiinfective agents.
Collapse
Affiliation(s)
- K A Rodvold
- College of Pharmacy, University of Illinois at Chicago, 60612, USA
| |
Collapse
|
8
|
Abstract
The pharmacokinetic characteristics of levofloxacin, moxifloxacin, and gatifloxacin include excellent oral bioavailability (90-99%), extensive penetration into tissues and body fluids, and an elimination half-life (6-12 hrs) that allows for once-daily dosing in patients with normal renal function. Levofloxacin and gatifloxacin primarily are excreted unchanged in the urine, whereas moxifloxacin undergoes hepatic metabolism. The pharmacodynamic values that correlate with successful clinical and microbiologic outcomes, as well as prevent emergence of bacterial resistance, are ratios of maximum or peak unbound drug concentration (Cmax) to minimum inhibitory concentration (MIC), and 24-hour unbound area under the concentration curve (AUC(0-24hr)) to MIC. For gram-negative infections, a Cmax:MIC greater than or equal to 10 and AUC(0-24hr):MIC greater than or equal to 125 are associated with increased probability of a successful outcome. For infections caused by Streptococcus pneumoniae, an AUC(0-24hr):MIC of 30 or more is suggested for favorable clinical outcomes. Pharmacokinetic and pharmacodynamic values influence rational therapeutic decisions in the selection and dosages of these drugs.
Collapse
Affiliation(s)
- K A Rodvold
- College of Pharmacy, University of Illinois at Chicago, 60612, USA.
| | | |
Collapse
|
9
|
Kays MB, Denys GA. Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana. Diagn Microbiol Infect Dis 2001; 40:193-8. [PMID: 11576793 DOI: 10.1016/s0732-8893(01)00277-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The in vitro activity and pharmacodynamics (AUC(0-24)/MIC) of levofloxacin, gatifloxacin, moxifloxacin, and gemifloxacin were evaluated against 307 clinical isolates of Streptococcus pneumoniae from Indianapolis, Indiana. Organisms were collected between January 1999 and April 2000, and MICs were determined by broth microdilution. Serum concentration-time profiles were simulated for the following oral regimens administered once daily: levofloxacin 500 mg and 750 mg; gatifloxacin 400 mg; moxifloxacin 400 mg; gemifloxacin 320 mg. Free 24 h area under the serum concentration-time curves (AUC(0-24)) were calculated, and the average AUC(0-24)/MIC was calculated for each regimen. Differences in AUC(0-24)/MIC among agents were determined by analysis of variance (Scheffe post-hoc test, p < 0.05). Overall, gemifloxacin was the most potent agent tested. Five (1.7%), 4 (1.3%), and 2 (0.7%) isolates were resistant to levofloxacin, gatifloxacin, and moxifloxacin, respectively. None of the isolates was resistant to gemifloxacin. Gemifloxacin AUC(0-24)/MIC was significantly greater than all other regimens (p < 0.0001), with the exception of moxifloxacin. However, the percent of isolates for which an AUC(0-24)/MIC >or= 30-50 can be achieved is similar for gemifloxacin, moxifloxacin, gatifloxacin, and levofloxacin 750 mg. Large comparative studies are needed to determine if the differences in AUC(0-24)/MIC among fluoroquinolones are clinically significant.
Collapse
Affiliation(s)
- M B Kays
- Department of Pharmacy Practice, Purdue University School of Pharmacy and Pharmacal Sciences, Indianapolis, Indiana 46202, USA.
| | | |
Collapse
|
10
|
Martin SJ, Jung R, Garvin CG. A Risk-Benefit Assessment of Levofloxacin in Respiratory, Skin and Skin Structure, and Urinary Tract Infections. Drug Saf 2001; 24:199-222. [PMID: 11347723 DOI: 10.2165/00002018-200124030-00004] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
As a class, the quinolone antibacterials can no longer be assumed to be both effective and relatively free of significant adverse effects. Recent safety issues with newer generation fluoroquinolones, and concerns regarding drug-use associated bacterial resistance have made all drugs in this class subject to intense scrutiny and further study. Levofloxacin is a second generation fluoroquinolone with a post marketing history of well tolerated and successful use in a variety of clinical situations. Quinolones as a class cause a variety of adverse effects, including phototoxicity, seizures and other CNS disturbances, tendonitis and arthropathies, gastrointestinal effects, nephrotoxicity, prolonged QTc interval and torsade de pointes, hypo- or hyperglycaemia, and hypersensitivity reactions. Levofloxacin has been involved in only a few case reports of adverse events, which include QTc prolongation, seizures, glucose disturbances, and tendonitis. Levofloxacin has been shown to be effective at dosages of 250mg to 500mg once-daily in clinical trials in the management of acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, skin and skin structure infections, and urinary tract infections. There are data suggesting that levofloxacin may promote fluoroquinolone resistance among the Streptococcus pneumoniae, and that clinical failures may result from this therapy. Other data suggest that fluoroquinolones with lower potency against Pseudomonas aeruginosa than ciprofloxacin, such as levofloxacin, may drive class-wide resistance to this pathogen. Levofloxacin is an effective drug in many clinical situations, but its cost is significantly higher than amoxicillin, erythromycin, or first and second generation cefalosporins. Because of the propensity to select for fluoroquinolone resistance in the pneumococcus and potentially other pathogens, levofloxacin should be an alternative agent rather than a drug-of-choice in routine community-acquired respiratory tract, urinary tract, and skin or skin structure infections. In areas with increasing pneumococcal beta-lactam resistance, levofloxacin may be a reasonable empiric therapy in community-acquired respiratory tract infections. Similarly, in patients with risk factors for infectious complications or poor outcome, levofloxacin may be an excellent empiric choice in severe community-acquired respiratory tract infections, urinary tract infections, complicated skin or skin structure infections, and nosocomial respiratory and urinary tract infections. Better clinical data are needed to identify the true place in therapy of the newer fluoroquinolones in common community-acquired and nosocomial infections. Until then, these agents, including levofloxacin, might best be reserved for complicated infections, infection recurrence, and infections caused by beta-lactam or macrolide-resistant pathogens.
Collapse
Affiliation(s)
- S J Martin
- The University of Toledo, College of Pharmacy, Ohio 43606, USA.
| | | | | |
Collapse
|
11
|
|